A NOVEL VACCINE CANDIDATE WITH DOUBLE ANTIVIRAL ACTIVITY AGAINST THE HIV-1 AND COVID-19

Human Immunodeficiency Virus (HIV) is an RNA retrovirus with great capacity for replication and mutation. It belongs to lentiviruses, which are characterized in that the interval between the initial infection and the beginning of the main symptoms is classified into two types: HIV-1 and HIV-2, which have 40-50% genetic homology and organization and similar genomics. HIV-1 is the cause of the global Acquired Immune Deficiency Syndrome (AIDS) pandemic while HIV-2, although it can also cause AIDS, is considered less pathogenic and less transmissible. Another differential characteristic of HIV-1 is its great genetic variability, which is contributing to making it difficult to understand the mechanisms by which the virus is capable of causing the acquired immune deficiency syndrome and which necessarily influences the development of diagnostic tests and its possibilities of prevention, the development of effective treatments and vaccines, or the appearance of resistance. We have designed a preventive vaccine in Silico aimed to protect against VIH-1 infection and transmission. One aim of this is to better understand potential dormant repositories of outbreaks and potential spread of those repositories, together with potential geogenic terrain factors. Here, we present miRNA-peptide fusion more stable as an antiviral. Our analysis identified a miRNA-peptide with theoretical fusion value stability FS=80.75 Cruz, to treat HIV-1, named LCR_2020_B0119. The vaccine candidate presents in Silico an inhibiting action against HIV-1 and coronavirus (covid-19), making its use possible as a new double-action antiviral vaccine: anti-HIV-1 and anti-covid-19.